Welcome to our dedicated page for Apellis Pharmaceuticals SEC filings (Ticker: APLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Apellis Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Apellis Pharmaceuticals's regulatory disclosures and financial reporting.
Apellis Pharmaceuticals (APLS) insider filing reports a proposed sale under Rule 144 by Timothy Sullivan. The notice lists a planned block of 10,000 shares to be sold through UBS with an aggregate market value of $280,000, and indicates a recent sale on 09/08/2025 of 32,729 shares generating gross proceeds of $911,829. The company has 126,289,910 shares outstanding, so the disclosed transactions represent a small fraction of total equity. The shares being offered were acquired via option exercises on 04/18/2024 in four lots totaling 10,000 shares, with cash payment recorded on the original acquisition dates.
Apellis Pharmaceuticals reported a Form 144 notice for a proposed sale of 32,729 shares of common stock through Fidelity Brokerage Services LLC with an aggregate market value of $911,829.94. The filing lists the approximate date of sale as 09/08/2025 and identifies the shares outstanding as 126,289,910. The notice discloses recent acquisitions of the shares: multiple restricted stock vesting events in January 2025 totaling 17,729 shares and an option-related item of 15,000 shares listed with a 09/08/2025 payment date described as Cash.
The filer certifies no undisclosed material adverse information and provides no reportable sales in the past three months. The form presents the broker, quantities, acquisition dates, nature of acquisition, and payment type but does not include the seller’s identity or reasons for sale.
Apellis Pharmaceuticals insider James G. Chopas, listed as VP/Chief Accounting Officer, reported a sale of 548 shares of Apellis common stock on 09/02/2025 at a price of $28.077 per share. The filing states that the shares were sold to cover tax withholding on Restricted Stock Units released on August 29, 2025. After the transaction, Chopas beneficially owns 53,657 shares, held directly. The Form 4 was signed by an attorney-in-fact on 09/03/2025. No other derivative transactions or additional material information are reported.
Apellis Pharmaceuticals insider Kelley Boucher received equity awards on 09/02/2025. The filing shows a grant of 30,476 restricted stock units that vest 25% annually over four years, subject to continued service or termination provisions. Following the grant, Ms. Boucher beneficially owns 97,658 shares of common stock.
The filing also reports a stock option award for 45,766 shares with an exercise price of $28.17, exercisable beginning 09/02/2026 under a four-year vesting schedule and expiring 09/02/2035. The Form 4 was signed by an attorney-in-fact on 09/03/2025.
Apellis Pharmaceuticals, Inc. (APLS) Form 144 reports a proposed sale of 548 shares of common stock through Fidelity Brokerage Services LLC with an aggregate market value of $15,386.20. The filing shows approximately 126,289,910 shares outstanding and lists the approximate sale date as 09/02/2025 on the NASDAQ. The shares were acquired by restricted stock vesting on 08/29/2025 and the stated nature of payment is compensation. The filer reports no securities sold in the past three months and includes the standard Rule 144 attestation regarding material nonpublic information.
Apellis Pharmaceuticals insider Leslie Meltzer received equity awards on August 26, 2025. The filing shows a grant of 61,804 restricted stock units (RSUs) that vest 25% annually over four years subject to continued service, and a stock option to purchase 92,592 shares with an exercise price of $16.20 that vests over four years (25% after one year, then monthly thereafter) and expires August 26, 2035. After the transactions, Meltzer beneficially owns 61,804 shares from the RSUs and 92,592 underlying the option, reported as direct ownership. The form was signed by an attorney-in-fact on behalf of Meltzer on September 2, 2025.
Apellis Pharmaceuticals filed an initial Form 3 reporting that Leslie Meltzer, the company's Chief Research and Development Officer and an officer/director, submitted a statement of beneficial ownership tied to an event dated 08/26/2025. The filing discloses that no securities are beneficially owned by the reporting person. The form was signed on behalf of Ms. Meltzer by an attorney-in-fact, David Watson, with a signature date of 09/02/2025. The filing includes the reporting person's Waltham, MA business address but contains no holdings, derivative positions, or other ownership details.
Cedric Francois, Chief Executive Officer and Director of Apellis Pharmaceuticals (APLS), reported insider sales on August 27–28, 2025. The Form 4 shows sales of 175,037 shares on 08/27/2025 at a weighted-average price of $28.19 and 49,963 shares on 08/28/2025 at a weighted-average price of $28.39, totaling 225,000 shares sold. The filing reports post-transaction beneficial ownership figures of 357,909 shares (after the 08/27 sale) and 307,946 shares (after the 08/28 sale). The report also discloses multiple indirect holdings held in trusts: 472,065 shares, 300,000 shares and 234,411 shares, with trustees named in the footnotes. Footnotes clarify weighted-average price ranges and the reporting persons limited beneficial interest in trust-held shares.
Apellis Pharmaceuticals (APLS) Form 144 reports a planned sale of 225,000 shares of common stock through UBS Financial Services on 08/27/2025, with an aggregate market value of $6,462,500. The filing identifies Cedric Francois as the person for whose account the shares are to be sold and notes prior acquisitions by option exercise: 160,037 shares on 02/27/2023 and 74,963 shares on 09/01/2023, both paid in cash. The filing also discloses a sale within the last three months: 159,090 shares sold on 07/17/2025 for $2,540,000. The filer certifies no undisclosed material adverse information is known.
Apellis Pharmaceuticals insider transaction: David O. Watson, General Counsel and officer of Apellis Pharmaceuticals (APLS), reported a scheduled sale of 5,000 shares of Apellis common stock on 08/18/2025 at a price of $27.80 per share under a 10b5-1 trading plan dated March 3, 2025. After the reported sale, Mr. Watson beneficially owns 123,730 shares directly, plus 10,000 held in a custodial account for his minor children and 70,136 shares held by The David O. Watson Irrevocable Trust of 2023 (for which he disclaims beneficial ownership except to the extent of pecuniary interest). The Form 4 was signed on 08/19/2025.